Scottish Medicines Consortium (SMC)

In October 2014, Dymista® was approved by the Scottish Medicines Consortium (SMC) for use within NHS Scotland.2

Assessment based on a broad range of evidence

Members of the SMC committee consider a broad range of evidence when deciding which medicines should be approved for use by NHS Scotland. Decisions are made from a broad perspective by including wide mixture of backgrounds among committee members, from clinicians – most of whom have a direct role in patient care – to three volunteer public partners, who ensure the views of the Scottish public are represented.2


Dymista® bottle

Indication under review: for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.

For patients in whom the combination of azelastine hydrochloride and fluticasone propionate nasal spray is an appropriate choice of therapy, Dymista® provides the two ingredients in a single nasal spray.


  • Scadding GK, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). Clin Exp Allergy 2017; 47(7): 856‑889.
  • Scottish Medicine Consortium (SMC). Available at Last accessed: November 2018.

The website you are trying to access is designed for healthcare professionals in the UK, the content is not designed for the general public.

Are you a UK healthcare professional?


hcp popup title

Mylan Connects is an online platform for UK health Professionals.

Across the website you will find news, blogs and product information.

Register to Mylan Connects today

Please note that the website contains promotional and non-promotional material including educational content and resources to help you and your patients.